Evaluation ofin vitro drug screening leads using experimental models of human ovarian cancer |
| |
Authors: | Karen G. Louie Thomas C. Hamilton Robert H. Shoemaker Robert C. Young Robert F. Ozols |
| |
Affiliation: | (1) Medicine Branch and Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 20892 Bethesda, Maryland, USA;(2) Northwestern University Medical Center, 333 Chestnut, 60521 Hinsdale, IL, USA |
| |
Abstract: | Summary Five compounds which were identified as potential new anticancer drugs inin vitro screening with the human tumor colony forming assay were selected for further evaluation usingin vitro andin vivo models of human ovarian cancer. Three of five compounds were found to inhibitin vitro colony formation of ovarian cancer cell lines derived from both untreated and combination chemotherapy refractory patients. One compound was also found to prolong survival in a human ovarian carcinoma xenograft model system. This compound, chloroquinoxaline sulfonamide, was selected for development and has shown preliminary indication of activity in phase I clinical testing. |
| |
Keywords: | drug screening for ovarian cancer |
本文献已被 SpringerLink 等数据库收录! |
|